Status:
WITHDRAWN
Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD
Lead Sponsor:
Lung Institute
Conditions:
COPD
Emphysema or COPD
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
The aim of this randomized, controlled crossover designed study is to compare the outcomes of receiving autologous, adult stem cells versus placebo among participants with chronic obstructive pulmonar...
Detailed Description
The purpose of the Lung Institute is to collect, minimally process, and administer a person's own stem cells and/or platelet rich plasma and deliver the product back to the patient same-day through an...
Eligibility Criteria
Inclusion
- Patients are included in treatment by self-referral and after consultation with a designated patient coordinator who determines initial eligibility, and then by the clinic nurse practitioner or physician of Lung Institute who determines final eligibility for inclusion. Patients must be diagnosed with chronic obstructive pulmonary disease (COPD) and be able to travel to the Dallas clinic location.
Exclusion
- Patients who are unable to provide informed consent, pregnant patients, prisoners, non-English speakers, patients with a history of cancer within the past 5 years, patients with active tuberculosis or pneumonia. Patients without a documented COPD diagnosis are excluded.
Key Trial Info
Start Date :
April 24 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 11 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03228121
Start Date
April 24 2017
End Date
September 11 2018
Last Update
September 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lung Institute Dallas
Dallas, Texas, United States, 75231